Agios Pharmaceuticals (NASDAQ:AGIO) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) saw an uptick in trading volume on Monday . 342,761 shares traded hands during trading, a decline of 43% from the previous session’s volume of 599,397 shares.The stock last traded at $33.25 and had previously closed at $32.19.

Analyst Ratings Changes

AGIO has been the subject of a number of research analyst reports. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $56.33.

Agios Pharmaceuticals Trading Up 2.2 %

The company’s 50-day simple moving average is $47.15 and its 200 day simple moving average is $45.63. The stock has a market cap of $2.05 billion, a P/E ratio of 3.16 and a beta of 0.87.

Insider Buying and Selling

In related news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.93% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC purchased a new stake in Agios Pharmaceuticals in the second quarter worth $37,000. Quest Partners LLC bought a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 363 shares during the last quarter. CWM LLC raised its position in shares of Agios Pharmaceuticals by 554.7% in the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,836 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of Agios Pharmaceuticals during the 3rd quarter valued at approximately $146,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.